-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the phase 3 KEYNOTE-181 study, pembrolizumab monotherapy compared to chemotherapy as a second-line therapy can prolong the overall survival of patients with advanced esophageal cancer (EC) with a programmed death ligand 1 combined with a positive score (CPS) ≥10
.
This article reports the results of the pre-determined health-related quality of life (HRQoL) analysis of squamous cell carcinoma (SCC) patients with CPS ≥10 in this study
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ EC Questionnaire (OES18) and EuroQol 5-dimensional Questionnaire (EQ-5D) were used to evaluate HRQoL
.
The data of patients who received ≥1 dose of study treatment and completed ≥1 HRQoL assessment were analyzed
Changes in EORTC QLQ-C30 GHS/QoL scores of patients in two treatment groups
A total of 387 SCC patients were included in the HRQoL analysis
.
At baseline and at week 9, compliance and completion rates for all three questionnaires in the two treatment groups were similar
Pain (A) and reflux (B) worsening time between the two treatment groups
Pain (hazard ratio [HR] 1.
22, 95% CI, 0.
79~1.
89), reflux (HR 2.
38, 95% CI, 1.
33~4.
25) and dysphagia (HR 1.
53, 95% CI, 1.
02~ 2.
31) The subscale results of deterioration time are also similar
.
In summary, patients with esophageal squamous cell carcinoma with CPS ≥ 10 have no significant difference in health-related quality of life with pembrolizumab monotherapy or chemotherapy maintenance treatment
.
.
Patients with esophageal squamous cell carcinoma with CPS ≥ 10 had no significant difference in their health-related quality of life with pembrolizumab monotherapy or chemotherapy maintenance treatment
Original source:
Antoine Adenis, et al.
Impact of Pembrolizumab Versus Chemotherapy as Second- Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 in this message
